Jade Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
JBIO$15.60+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber | Description | Form | Date | Number | Included Herewith |
|---|---|---|---|---|---|
| 2.1† | Agreement and Plan of Merger, dated as of October 30, 2024, by and among Aerovate Therapeutics, Inc., Caribbean Merger Sub I, Inc., Caribbean Merger Sub II, LLC and Jade Biosciences, Inc. | 8-K | 10-31-2024 | 2.1 | |
| 2.2 | Plan of Conversion. | 8-K | 5-1-2025 | 2.2 | |
| 3.1 | Articles of Incorporation of the Company. | 8-K | 5-1-2025 | 3.4 | |
| 3.2 | Bylaws of the Company. | 8-K | 5-1-2025 | 3.5 | |
| 3.3 | Certificate of Designation of Series A Non-Voting Convertible Preferred Stock, effective April 28, 2025. | 8-K | 5-1-2025 | 3.7 | |
| 4.1 | Form of Pre-Funded Warrant, dated April 28, 2025. | 8-K | 5-1-2025 | 4.1 | |
| 4.2 | Form of Pre-Funded Warrant (October 2025 PIPE). | 8-K | 10-7-2025 | 4.1 | |
| 4.3 | Parade Warrant, dated December 31, 2025. | 10-K | 3-6-2026 | 4.3 | |
| 10.1# | Jade Biosciences, Inc. 2026 Employment Inducement Stock Incentive Plan. | X | |||
| 10.2# | Form of Grant Notice for Stock Options and Standard Terms and Conditions for Stock Options under the Jade Biosciences, Inc. 2026 Employment Inducement Stock Incentive Plan. | X | |||
| 10.3# | Form of Grant Notice for Restricted Stock Units and Standard Terms and Conditions for Restricted Stock Units under the Jade Biosciences, Inc. 2026 Employment Inducement Stock Incentive Plan. | X | |||
| 10.4# | Amended and Restated Employment Agreement, between Jade Biosciences, Inc. and Elizabeth Balta, dated as of February 25, 2026. | 10-K | 3-6-2026 | 10.17 | |
| 10.5††† | Amendment No. 2 to the APRIL License Agreement, dated as of October 15, 2025, by and between Paragon Therapeutics, Inc. and Jade Biosciences, Inc. | X | |||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
- Furnished herewith. The certifications on Exhibits 32.1 and 32.2 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.